ClinicalTrials.gg
RecruitingNCT06849596MVPUpdated Oct 9, 2026

Manual T-piece Versus Ventilator Positive Pressure Ventilation During Resuscitation of Extremely Premature Neonates

An interventional study of Ventilator derived positive pressure ventilation - V-PPV and T-piece resuscitator (TPR) in Neonatal Resuscitation and Apnea Neonatal, sponsored by Michelle Baczynski. Recruiting at 11 sites in 3 countries. Open to participants aged 25 Weeks to 29 Weeks. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Michelle Baczynski · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 9, 2026Site recruiting status changedSponsor changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
25 Weeks to 29 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.

Planned enrollment
16th of 106
780 · median 80
Started
2025
with 6 others
No phase
65 of 139
9 open now
Primary completion
2028-09
later than 27 of 33 live
Registered
127th of 139
by date

Among the 139 studies in Premature Birth with a site in Canada, this one is the 16th largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2025, is one of 65 with no phase, reaches primary completion later than 27 of the 33 other live ones, and was the 127th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 25 Weeks to 29 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Premature Birth with a site in Canada, or all of them as a file.
02

Study summary

Many extremely premature infants require immediate help with breathing after birth. Positive pressure ventilation (PPV) using a device called a T-piece resuscitator is a common method. PPV is needed to establish proper lung function, improve gas exchange, and encourage the infant to breathe spontaneously. However, T-piece resuscitators have limitations, like a lack of visual feedback and variable settings, which may result in reduced effectiveness of PPV. Improving PPV effectiveness may reduce the need for more invasive procedures, such as intubation, which pose an increased risk of complications and death for these fragile infants. A novel approach, that may overcome the above limitations and deliver PPV with precise settings through a nasal mask, is to use a ventilator to deliver PPV (V-PPV) using a respiratory mode called nasal intermittent positive pressure ventilation (NIPPV). While NIPPV is commonly used in neonatal intensive care units to support breathing in premature infants, the impact of V-PPV use during immediate post-birth stabilization needs to be studied. Preliminary data from our recent single-center study confirmed the feasibility of using V-PPV for resuscitation of extremely premature babies and indicated its potential superiority with a 28% decrease in the need for intubation compared to historical use of T-piece. This promising innovation may enhance outcomes for these vulnerable infants by refining the way we provide respiratory support in their critical first moments. The research objective is to compare the clinical outcomes of extremely premature infants receiving manual T-piece versus V-PPV during immediate post-birth stabilization. The primary aim is to evaluate the impact of V-PPV on major health complications or death. This study seeks to provide insights into improving the care and outcomes of these infants during a critical stage of transition from fetus to newborn.

03

Conditions studied

  • Neonatal Resuscitation
  • Apnea Neonatal

Keywords

  • Premature Infant
  • Preterm Neonates
  • Oxygen
  • Lung Injury
  • Respiration, Artificial
  • Resuscitation
  • Ventilator, Mechanical
04

Who can participate

Ages eligible
25 Weeks to 29 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria::

  • GA 25+0 to 28+6 weeks using the best available obstetrical estimate
  • Designated to receive full resuscitation, i.e., not pre-determined to receive only comfort care
  • Received PPV as determined by the resuscitation team during the first 10 minutes of birth

Exclusion Criteria:

  • Outborn birth status
  • Resuscitation performed in unforeseen circumstances outside typical delivery room (e.g., emergency department, antenatal ward)
  • Known major congenital or chromosomal anomaly
  • Established spontaneous respiration without receipt of PPV
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
780 participants (estimated)

Study arms

  • Active comparator
    Control group (T-Piece Resuscitator)

    Positive pressure ventilation during the first 10 minutes after birth will be provided with a T-Piece Resuscitator (TPR; Neopuff, Fisher \& Paykel Healthcare) connected to an appropriately sized face-mask, with settings adjustable within specified ranges for positive inspiratory pressure, positive end expiratory pressure, and fraction of inspired oxygen based on local policy. These specified ranges will be standardized across sites.

    Device: T-piece resuscitator (TPR)

  • Experimental
    Intervention under investigation (Ventilator delivered PPV)

    Positive pressure ventilation (PPV) during the first 10 minutes after birth will be provided using a neonatal ventilator set up in noninvasive positive pressure ventilation (NIPPV) mode, connected to an appropriately sized nasal mask or prongs and a dual limb neonatal ventilator circuit, with settings adjustable within specified ranges for positive inspiratory pressure, positive end expiratory pressure, respiratory rate and inspiratory time and fraction of inspired oxygen based on local policy. These specified ranges will be standardized across sites.

    Device: Ventilator derived positive pressure ventilation - V-PPV

Interventions

  • DeviceVentilator derived positive pressure ventilation - V-PPV

    The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. Ventilator delivered positive pressure ventilation (V-PPV) using a nasal interface will be delivered to the infant in the resuscitation room.

  • DeviceT-piece resuscitator (TPR)

    The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. PPV will be provided with a T-piece resuscitator (Neopuff, Fisher \& Paykel Healthcare) connected to an appropriately sized face-mask.

06

What researchers measure

Primary outcomes

  1. Composite of pre-discharge mortality

    Death in NICU

    Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)

  2. Major neuro-injury

    Defined as IVH ≥grade 3, cerebellar hemorrhage or periventricular leukomalacia.

    Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)

  3. Moderate-severe BPD

    Defined as 2 L/min nasal cannula or other forms of non-invasive ventilation support or invasive mechanical ventilation.

    Time frame: At 36 weeks' postmenstrual age.

Secondary outcomes

  1. Components of the primary outcome

    Pre-discharge mortality, major neuro-injury or moderate-severe BPD

    Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)

  2. Frequency of receipt of advanced cardiopulmonary resuscitation measures

    Chest compressions or epinephrine administration for the purpose of resuscitation.

    Time frame: From enrollment to 1 hour post intervention.

  3. Duration of invasive mechanical ventilation during NICU admission

    Total number of days on invasive mechanical ventilation

    Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)

  4. Discharge on home oxygen

    Discharge from the NICU requiring oxygen support at home

    Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)

  5. Other relevant key prematurity related adverse outcome

    Necrotizing enterocolitis ≥ stage 2a, retinopathy of prematurity needing treatment.

    Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)

07

Study locations

7 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2028, 33 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 33 months is above that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Feb 27, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Jan 1, 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Children's Hospital at London Health Sciences Centre is now Withdrawn
Show site
  • Sunnybrook Health Sciences Centre · Toronto, Canada
Oct 9, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Cedars-Sinai Guerin Children's · Los Angeles, United StatesContact added (no phone or email listed)
  • Children's Hospital at London Health Sciences Centre · London, CanadaContact removed k•••@lhsc.on.ca · •••8500Contact removed (no phone or email listed)
  • Mount Sinai Hospital · Toronto, CanadaContact added (no phone or email listed)
  • Rigshospitalet Coppenhagen · Copenhagen, DenmarkContact added (no phone or email listed)
Oct 9, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: London Health Sciences Centre
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added. Children's Hospital at London Health Sciences Centre is now Withdrawn
    Show site
    • Sunnybrook Health Sciences Centre · Toronto, Canada
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: London Health Sciences Centre
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Cedars-Sinai Guerin Children's · Los Angeles, United StatesContact added (no phone or email listed)
    • Children's Hospital at London Health Sciences Centre · London, CanadaContact removed k•••@lhsc.on.ca · •••8500Contact removed (no phone or email listed)
    • Mount Sinai Hospital · Toronto, CanadaContact added (no phone or email listed)
    • Rigshospitalet Coppenhagen · Copenhagen, DenmarkContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06849596
Lead sponsor
Michelle Baczynski
Collaborators
Royal Alexandra Hospital, Foothills Medical Centre, McMaster Children's Hospital, St. Justine's Hospital, Cedars-Sinai Medical Center, Montreal Children's Hospital of the MUHC, Sunnybrook Health Sciences Centre, BC Women's Hospital & Health Centre, Copenhagen University Hospital, Rigshospitalet
Responsible party
Michelle Baczynski (Respiratory Therapist, Mount Sinai Hospital, Canada) — Sponsor-investigator
First posted
Feb 27, 2025
Start date
Dec 1, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Thaiani Wulff, BSc
Contact
thaiani.wulff@sinaihealth.ca
1-416-586-4800. ext. 176746
Laura Thomas, MSc
Contact
laura.thomas@sinaihealth.ca
416-586-4800 ext. 172060
Michelle Baczynski, MSc, RRT
principal investigator · MOUNT SINAI HOSPITAL
Amish Jain, MBBS, MRCPCH, PhD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion